Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Does lineage plasticity enable escape from CAR-T cell therapy? Lessons from MLL-r leukemia

21 Jul 2021

Abstract excerpt

The clinical success of engineered, CD19-directed chimeric antigen receptor (CAR) T cells in relapsed, refractory B-cell acute lymphoblastic leukemia (B-ALL) has generated great enthusiasm for the use of CAR T cells in patients with cytogenetics that portend a poor prognosis with conventional cytotoxic therapies. One such group includes infants and children with mixed lineage leukemia (MLL1, KMT2A )...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 34298117
DOI: 10.1016/j.exphem.2021.07.002

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Does lineage plasticity enable escape from CAR-T cell therapy? Lessons from MLL-r leukemiaPMID 34298117Read ↗

To B‐ or not to B‐: A review of lineage switched acute leukemiaSemantic proximity Read ↗

Genetics and pathologic landscape of lineage switch of acute leukemia during therapySemantic proximity Read ↗

The dynamic evolution of lineage switch under CD19 CAR-T treatment in non-KMT2A rearranged B-ALL patientsSemantic proximity Read ↗

CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity.Semantic proximity Read ↗

CD19‐directed immunotherapy use in KMT2A‐rearranged acute leukemia: A case report and literature review of increased lymphoid to myeloid lineage switchSemantic proximity Read ↗

Tracking The Molecular Dynamics of Lineage Switch Under CD19 CAR-T Treatment in Non-KMT2A Rearranged B-ALL PatientsSemantic proximity Read ↗

Clonal origin of KMT2A wild-type lineage-switch leukemia following CAR-T cell and blinatumomab therapySemantic proximity Read ↗

CRLF2 -rearranged B-cell ALL with extramedullary lineage switch to AML following CD19-targeted therapySemantic proximity Read ↗

Donor-derived CD19-CAR-T therapy in combination with TKI cure uncommon CRLF2r- Mixed Phenotype Acute Leukemia lineage switch to Ph+ Acute Lymphoblastic LeukemiaSemantic proximity Read ↗

Cars in Leukemia: Relapse with Antigen-Negative Leukemia Originating from a Single B Cell Expressing the Leukemia-Targeting CARSemantic proximity Read ↗

Molecular signature of pediatric B-ALL determines outcomes post CD19 CAR-T cell therapySemantic proximity Read ↗

Favorable response of a patient with primary B/myeloid mixed phenotype acute Leukemia to CD19-CAR-T: Case report and literature review.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.